Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caladrius acquires license to CD34+ cell therapy program from Shire
Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment
Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment
These trials will evaluate the effect of Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure independent of whether they have type 2
The submission acceptance is based on Phase III data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes) clinical programme for Forxiga in T1D.
The multi-year collaboration is focused on the identification and development of unique small molecules against targets for a range of oncology, inflammatory and neurodegenerative indications. The collaboration is
Per the Prescription Drug User Fee Act, the target action date is October 20, 2018. Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4
Mylan anticipates introducing Symfi Lo in the coming weeks and Cimduo in the second quarter of this year. These upcoming launches will extend Mylan's global antiretroviral (ARV) platform
This is a result of the company’s 2025 strategy which increases the focus on new innovative solutions for medical dermatology and no longer pursue over-the-counter (OTC) in most
In just under nine months, the Company has now raised over $220 million. Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics (RCT)
BOTOX is the market-leading neuromodulator approved for the treatment of multiple indications and usage in the United States with additional approvals globally. The addition of this product further
Under the terms of the agreement, GSK will use Covance Xcellerate® Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model. Covance technology products